Noteworthy, only 8.4 and 11.2% of patients, respectively, developed a febrile neutropaenia, showing that the prescription of G-CSF aimed predominantly to facilitate neutrophil recovery and to maintain RDI rather than to prevent secondary infections. This evidence concerns the gene CSF3 and infection.